Previous 10 | Next 10 |
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be releas...
2023-07-25 10:38:13 ET Summary 22 out of 22 CEF sectors positive on price and 22 out of 22 sectors positive on NAV last week. BlackRock continues repurchasing shares. Amount purchased fell from last quarter as discounts narrowed slightly. The Weekly Closed-End Fund...
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit from a change in their breast care SALT LAKE CITY, July 24, 2023 (GLOBE NEWSWIRE) -- ...
SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million asset-based credit facility (the “ABL Facility”) with JPMorgan Chase Bank, N.A....
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma trea...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of the following BlackRock funds concerning the Company and its directors’ and officers’ possible violations of state laws: If you own stock in one or more of these BlackRock funds, would like to l...
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will participate in the 44 th Annual Goldman Sachs Global Healthcare Conference with a fireside ch...
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical ...
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit. In his new role, Dr. Brufsky is responsib...
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE ® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of...
News, Short Squeeze, Breakout and More Instantly...
Blackrock MuniYield Fund Inc. Company Name:
MYD Stock Symbol:
NYSE Market:
Blackrock MuniYield Fund Inc. Website:
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experi...
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company’s quarterly earnings will be released ...
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition , which revealed that a majority (63%) of women do not know th...